|
Nephritis
|
0.200 |
Biomarker
|
disease |
RGD |
Macrophage epoxygenase determines a profibrotic transcriptome signature.
|
25840911 |
2015 |
|
Other ureteric obstruction
|
0.200 |
Biomarker
|
phenotype |
RGD |
Macrophage epoxygenase determines a profibrotic transcriptome signature.
|
25840911 |
2015 |
|
Pre-Eclampsia
|
0.200 |
Biomarker
|
phenotype |
RGD |
Stimulating a trophoblast-derived cell line with the preeclampsia-associated cytokine tumor necrosis factor-α enhanced CYP2J2 gene and protein expression.
|
23155181 |
2012 |
|
Pneumonia, Bacterial
|
0.200 |
Biomarker
|
group |
RGD |
Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia.
|
14766666 |
2004 |
|
Sepsis
|
0.200 |
Biomarker
|
disease |
RGD |
Differential expression of cytochrome P450 isoforms in the lungs of septic animals.
|
15190971 |
2004 |
|
Renal hypertension
|
0.200 |
Biomarker
|
disease |
RGD |
Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.
|
10779386 |
2000 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the rs2280275 and rs11572325 SNPs of CYP2J2 may be considered novel genetic markers of hypertension, at least in Russian women.
|
30518987 |
2019 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies have shown that overexpression of CYP2J2 in vivo reverses several pathological processes in animals, including hypertension and other cardiovascular pathologies and insulin resistance.
|
27286171 |
2016 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study showed positive association of CYP2J2 gene polymorphism with hypertension among Saudi cases.
|
22731644 |
2012 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data implicate CYP2J2 in the pathogenesis of preeclampsia and as a potential candidate for the disturbed uteroplacental remodeling, leading to hypertension and endothelial dysfunction.
|
23155181 |
2012 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated whether gene delivery with the human cytochrome P450 epoxygenase 2J2 (CYP2J2) ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats.
|
20118222 |
2010 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
LHGDN |
The frequency of a -50T variant allele of CYP2J2 gene was significantly higher in patients with hypertension versus healthy controls (OR 4.03 95%CI 1.80-9.04 p=0.0004).
|
18219097 |
2008 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequency of a -50T variant allele of CYP2J2 gene was significantly higher in patients with hypertension versus healthy controls (OR 4.03 95%CI 1.80-9.04 p=0.0004).
|
18219097 |
2008 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multiple logistic regression analysis showed four independent risk factors: the CYP2J2*7 T allele (OR 1.78, 95% confidence interval [CI] 1.1-6.4; p=0.02), smoking (OR 3.05, 95% CI 1.6-7.3; p<0.01), diabetes mellitus (OR 3.24, 95% CI 1.2-6.6; p<0.01), and hypertension (OR 1.95, 95% CI 1.1-5.7; p<0.01).
|
17126841 |
2007 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Evidence from animal models and human studies suggests that CYP2J2 plays a mechanistic role in the development of hypertension.
|
17286575 |
2007 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
LHGDN |
Evidence from animal models and human studies suggests that CYP2J2 plays a mechanistic role in the development of hypertension.
|
17286575 |
2007 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study provides evidence for an association between CYP2J2*7 genotype and hypertension in Caucasian males and Caucasians without a family history of hypertension, but suggests no association between CYP2C8*3 genotype and hypertension.
|
15864120 |
2005 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated the frequency of the CYP2J2*6 variant in a Caucasian population and the relationship between this polymorphism and the development of micro- and macrovascular complications and hypertension in patients with type 1 or type 2 diabetes mellitus.
|
14575523 |
2003 |
|
Coronary Arteriosclerosis
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We previously demonstrated that OP-D-mediated cardioprotection involves activation of CYP2J2/3 and enhancement of circulating EETs levels in vitro and can be developed as a novel drug for the therapy of myocardial ischemia-reperfusion (MI/R) injury.
|
30227401 |
2018 |
|
Coronary Arteriosclerosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
This is the first study showing significant gene-sex interaction for CYP2C8*3 with twofold increase in the relative risk of essential hypertension and a similar tendency for CYP2J2*7 associated with coronary artery disease without myocardial infarction in Bulgarian males.
|
26404779 |
2015 |
|
Coronary Arteriosclerosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China.
|
23684773 |
2013 |
|
Coronary Arteriosclerosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C or CYP2J2 have a pathologic impact on coronary artery diseases.
|
21476972 |
2011 |
|
Coronary Arteriosclerosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.
|
21642892 |
2011 |
|
Coronary Arteriosclerosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The CYP2J2-G-50T-promotor polymorphism decreases gene expression and is associated with coronary artery disease.
|
19105833 |
2008 |
|
Coronary Arteriosclerosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine if genetic variation in CYP2J2 and CYP2C8 was associated with coronary heart disease risk.
|
17429317 |
2007 |